Document:

Execution
Copy

 

STOCK PURCHASE AGREEMENT

 

         THIS
STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 12, 2013, by and among Titan Pharmaceuticals,
Inc., a Delaware corporation with headquarters located at 400 Oyster Point Blvd., Suite 505, South San Francisco, California 94080
(the “Company”), and the investor identified on the signature pages hereto (the “Investor”).

 

PREAMBLE

 

A.         
The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from registration afforded
by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act.

 

B.         
The Investor wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that
aggregate number of shares of the common stock, par value $0.001 per share, of the Company (the “Common Stock”),
set forth on the Investor’s signature page to this Agreement (which aggregate amount shall be six million two hundred fifty
thousand (6,250,000) shares of Common Stock and shall collectively be referred to herein as the
“Common Shares”). The purchase price per share shall be eighty cents ($0.80), or five million dollars ($5,000,000)
in the aggregate.

 

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Business
Day” means any day other than Saturday, Sunday, any day which shall be a federal legal holiday in the United States or
any day on which banking institutions in The State of New York are authorized or required by law or other governmental action to
close.

 

    	 

    	 

    

 

“Closing”
means the closing of the purchase and sale of the Common Shares pursuant to Section 2.1.

 

“Closing Date”
means the date and time of the Closing and shall be on such date and time as is mutually agreed to by the Company and the Investor,
but in no event later than the tenth Trading Day after the date of this Agreement.

 

“Company”
has the meaning set forth in the Preamble.

 

“Company Counsel”
means Loeb & Loeb LLP, counsel to the Company.

 

“Common Shares”
has the meaning set forth in the Preamble.

 

“Common Stock”
has the meaning set forth in the Preamble.

 

“Convertible
Securities” means any stock or securities (other than Options) convertible into or exercisable or exchangeable for Common
Stock.

 

“Disclosure
Materials” has the meaning set forth in Section 3.1(f).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“GAAP”
has the meaning set forth in Section 3.1(g).

 

“Indemnified
Party” has the meaning set forth in Section 6.3(c).

 

“Indemnifying
Party” has the meaning set forth in Section 6.3(c).

 

“Intellectual
Property Rights” has the meaning set forth in Section 3.1(m).

 

“Investor”
has the meaning set forth in the Preamble. 

 

“Lien”
means any lien, charge, claim, security interest, encumbrance, right of first refusal or other restriction.

 

“Losses”
means any and all losses, claims, damages, liabilities, settlement costs and expenses, including, without limitation, reasonable
attorneys’ fees.

 

“Material
Adverse Effect” means (i) a material adverse effect on the results of operations, assets, business, prospects or financial
condition of the Company or (ii) material and adverse impairment of the Company's ability to perform its obligations under
any of the Transaction Documents, provided, that none of the following alone shall be deemed, in and of itself, to constitute a
Material Adverse Effect: (i) a change in the market price or trading volume of the Common Stock or (ii) changes in general economic
conditions or changes affecting the industry in which the Company operates generally (as opposed to Company-specific changes) so
long as such changes do not have a disproportionate effect on the Company.

 

    	-2-

    	 

    

 

“Material
Permits” has the meaning set forth in Section 3.1(m).

 

“Options”
means any outstanding rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.

 

“Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
a government or any department or agency thereof and any other legal entity.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, a partial proceeding, such as a deposition),
whether commenced or threatened in writing.

 

“Prospectus”
means the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of
any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the
Prospectus including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.

 

“Registrable
Securities” means the Common Shares issued or issuable pursuant to the Transaction Documents, together with any securities
issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the
foregoing; provided that Common Shares shall cease to be Registrable Securities upon the earliest to occur of the following:
(A) sale pursuant to a Registration Statement or Rule 144 under the Securities Act (in which case, only such security sold shall
cease to be a Registrable Security); or (B) becoming eligible for sale without volume limitations by the Holder pursuant to Rule
144(b).

 

“Registration
Statement” means any registration statement filed under Article VI filed after the Closing Date, including (in each
case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such
registration statement.

 

“Regulation
D” has the meaning set forth in the Preamble. 

 

    	-3-

    	 

    

 

“Rule 144,”
“Rule 415,” and “Rule 424” means Rule 144, Rule 415 and Rule 424,
respectively, promulgated by the SEC pursuant to the Securities Act, as such Rules may be amended from time to time, or any similar
rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.

 

“SEC”
has the meaning set forth in the Preamble.

 

“SEC Reports”
has the meaning set forth in Section 3.1(f).

 

“Securities
Act” has the meaning set forth in the Preamble. 

 

“Shares”
means shares of the Company’s Common Stock.

 

“Short
Sales” means all “short sales” as defined in Rule 200 promulgated under
Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts,
calls, swaps, derivatives and similar arrangements.

 

“Trading Day”
means (i) a day on which the Common Stock is traded on a Trading Market (other than the OTC Bulletin Board), or (ii) if the Common
Stock is not listed or quoted on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded
in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not listed or quoted on
any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink Sheets LLC
(or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common
Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.

 

“Trading Market”
means whichever of the New York Stock Exchange, the NYSE/Amex, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ
Capital Market or OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.

 

“Transaction
Documents” means this Agreement and the documents and instruments to be delivered hereunder.

 

“Transfer
Agent” means Continental Stock Transfer & Trust Company, or any successor transfer agent for the Company.

 

ARTICLE II

PURCHASE AND SALE

 

2.1Closing.
Subject to the terms and conditions set forth in this Agreement, at the Closing the Company shall issue and sell to the Investor,
and the Investor shall purchase from the Company, such number of Common Shares for the price set forth on the Investor’s
signature page to this Agreement. The date and time of the Closing and shall be 11:00 a.m., New York City Time, on the Closing
Date. The Closing shall take place at the offices of Company Counsel on the Closing Date.

 

    	-4-

    	 

    

 

2.2Closing Deliveries.

 

(a)At the Closing,
the Company shall deliver or cause to be delivered to the Investor the following:

 

(i)a copy of the
Company’s irrevocable instructions to the Transfer Agent instructing the Transfer Agent to promptly deliver one or more stock
certificates, free and clear of all restrictive and other legends (except for a customary legend to the effect that the Common
Shares have not been registered under the Securities act), evidencing such number of Common Shares set forth on the Investor’s
signature page to this Agreement, registered in the name of the Investor; and

 

(ii)a
legal opinion of Company Counsel, in the form of Exhibit A, executed by such counsel and delivered to the Investors.

 

(b)At the Closing,
the Investor shall deliver or cause to be delivered to the Company the purchase price set forth on the Investor’s signature
page to this Agreement in United States dollars and in immediately available funds, by wire transfer to an account designated in
writing to the Investor by the Company for such purpose.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

3.1Representations
and Warranties of the Company. The Company hereby represents and warrants to the Investor that, except as set forth in the
SEC Reports:

 

(a)Organization
and Qualification. The Company is an entity duly organized, validly existing and in good standing under the laws of the State
of Delaware, with the requisite legal authority to own and use its properties and assets and to carry on its business as currently
conducted. The Company is not in violation of any of the provisions of its certificate of incorporation, bylaws or other organizational
or charter documents. The Company is duly qualified to do business and is in good standing as a foreign corporation or other entity
in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect.

 

(b)Authorization;
Enforcement. The Company has the requisite corporate authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder including the issuance and sale of the Common Shares. The
execution and delivery of each this Agreement by the Company and the consummation by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on the part of the Company and no further consent or action is required
by the Company, its Board of Directors or its stockholders. This Agreement has been duly executed by the Company and is the valid
and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.

 

    	-5-

    	 

    

 

(c)No
Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not, and will not, (i) conflict with or violate any provision of the Company’s
certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company is a party
or by which any property or asset of the Company is bound, or affected, except to the extent that such conflict, default, termination,
amendment, acceleration or cancellation right would not reasonably be expected to have a Material Adverse Effect, or (iii) result
in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company is subject (including, assuming the accuracy of the representations and warranties of the Investors
set forth in Section 3.2 hereof, federal and state securities laws and regulations and the rules and regulations of any
self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets), or
by which any property or asset of the Company is bound or affected, except to the extent that such violation would not reasonably
be expected to have a Material Adverse Effect.

 

(d)The
Common Shares.The Common Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will
be duly and validly issued, fully paid and nonassessable, free and clear of all Liens and will not be subject to preemptive or
similar rights of stockholders (other than those imposed by the Investors).

 

(e)Capitalization.
The aggregate number of shares and type of all authorized, issued and outstanding classes of capital stock, options and other securities
of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company)
is set forth in the Company’s SEC Reports. All outstanding shares of capital stock are duly authorized, validly issued, fully
paid and nonassessable and have been issued in compliance in all material respects with all applicable securities laws. Except
as disclosed in the SEC Reports, the Company did not have outstanding at September 1, 2012 any other Options, script rights to
subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or entered into any agreement giving any Person any right to subscribe for or acquire, any
shares of Common Stock, or securities or rights convertible or exchangeable into shares of Common Stock. Except as set forth in
the SEC Reports, and except for customary adjustments as a result of stock dividends, stock splits, combinations of shares, reorganizations,
recapitalizations, reclassifications or other similar events, there are no anti-dilution or price adjustment provisions contained
in any security issued by the Company (or in any agreement providing rights to security holders) and the issuance and sale of the
Common Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investors)
and will not result in a right of any holder of securities to adjust the exercise, conversion, exchange or reset price under such
securities.

 

    	-6-

    	 

    

 

(f)SEC
Reports; Financial Statements. The Company has filed all reports required to be filed by it under the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding the date hereof on a timely basis or
has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension
and has filed all reports required to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the two years preceding the date hereof. Such reports required to be filed by the Company under the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, together with any materials filed or furnished by the Company under the Exchange Act,
whether or not any such reports were required being collectively referred to herein as the “SEC Reports” and,
together with this Agreement, the “Disclosure Materials”. As of their respective dates (or, if amended or superseded
by a filing prior to the Closing Date, then on the date of such filing), the SEC Reports filed by the Company complied in all material
respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated
thereunder, and none of the SEC Reports, when filed (or, if amended or superseded by a filing prior to the date hereof, then on
the date of such filing) by the Company, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing (or, if amended or superseded by a filing prior to the Closing Date, then on the date of such filing). Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements,
the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP or may be condensed
or summary statements, and fairly present in all material respects the financial position of the Company as of and for the dates
thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, year-end audit adjustments. All material agreements to which the Company is a party or to which the property or assets
of the Company are subject are included as part of or identified in the SEC Reports, to the extent such agreements are required
to be included or identified pursuant to the rules and regulations of the SEC.

 

    	-7-

    	 

    

 

(g)Material
Changes; Undisclosed Events, Liabilities or Developments; Solvency. Since the date of the latest audited financial statements
included within the SEC Reports, (i) there has been no event, occurrence or development that, individually or in the aggregate,
has had or would result in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company's financial statements pursuant to GAAP or required to be disclosed in filings made
with the SEC, (iii) the Company has not altered its method of accounting or changed its auditors, (iv) the Company has
not declared or made any dividend or distribution of cash or other property to its stockholders, in their capacities as such, or
purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has
not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock-based plans.
The Company has not taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or
reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact
which would reasonably lead a creditor to do so.

 

(h)Absence
of Litigation. There is no action, suit, claim, or Proceeding, or, to the Company's knowledge, inquiry or investigation, before
or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company,
threatened against or affecting the Company that could, individually or in the aggregate, to have a Material Adverse Effect.

 

(i)Compliance.
Except as would not, individually or in the aggregate, reasonably be expected to have or result in a Material Adverse Effect, (i) 
the Company is not in default under or in violation of (and no event has occurred that has not been waived that, with notice or
lapse of time or both, would result in a default by the Company under), nor has the Company received written notice of a claim
that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument
to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived),
(ii)  the Company is not in violation of any order of any court, arbitrator or governmental body, or (iii)  the Company
is not and has not been in violation of any statute, rule or regulation of any governmental authority.

 

    	-8-

    	 

    

 

(j)
Private Placement; Investment Company; U.S. Real Property Holding Corporation. Neither the Company nor any of its Affiliates
nor, any Person acting on the Company’s behalf has, directly or indirectly, at any time within the past six months, made
any offer or sale of any security or solicitation of any offer to buy any security under circumstances that would (i) eliminate
the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer
and sale by the Company of the Common Shares as contemplated hereby or (ii) cause the offering of the Common Shares pursuant
to the Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable law, regulation
or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market. Assuming
the accuracy of the representations and warranties of the Investor set forth in Section 3.2, no registration under the Securities
Act is required for the offer and sale of the Common Shares by the Company to the Investors as
contemplated hereby. The Company is not required to be registered as, and is not an Affiliate of, an
“investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company is not required
to be registered as a United States real property holding corporation within the meaning of the Foreign Investment in Real Property
Tax Act of 1980.

 

(k)Disclosure.
To the Company's knowledge, no event or circumstance has occurred or information exists with respect to the Company or its business,
properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement
by the Company but which has not been so publicly announced or disclosed.

 

(l)
Patents and Trademarks. The Company owns, or possesses adequate rights or licenses to use, all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets and other intellectual property rights (“Intellectual Property Rights”) necessary
to conduct its business as now conducted. None of the Company’s Intellectual Property Rights have expired or terminated,
or are expected to expire or terminate within three years from the date of this Agreement. The Company does not have any knowledge
of any infringement by the Company of Intellectual Property Rights of others. There is no claim, action or proceeding being made
or brought, or to the knowledge of the Company, being threatened, against the Company regarding its Intellectual Property Rights.

 

    	-9-

    	 

    

 

(m)Regulatory
Permits. The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local
or foreign regulatory authorities necessary to conduct its respective business as presently conducted and described in the SEC
Reports (“Material Permits”), except where the failure to possess such permits does not, individually or in
the aggregate, have or reasonably be expected to result in a Material Adverse Effect, and the Company has not received any written
notice of proceedings relating to the revocation or modification of any Material Permit.

 

3.2 Representations
and Warranties of the Investor. The Investor hereby represents and warrants to the Company as follows:

 

(a)Organization;
Authority. The Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite corporate, partnership or other power and authority to enter into and to consummate the
transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
purchase by the Investor of the Common Shares hereunder has been duly authorized by all necessary corporate, partnership or other
action on the part of the Investor. This Agreement has been duly executed and delivered by the Investor and constitutes the valid
and binding obligation of the Investor, enforceable against it in accordance with its terms, except (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.

 

(b)
Investor Status. At the time the Investor was offered the Common Shares, it was, at the date hereof it is an “accredited
investor” as defined in Rule 501(a) under the Securities Act or a “qualified institutional buyer” as defined
in Rule 144A(a) under the Securities Act. Such Investor is not a registered broker dealer registered under Section 15(a) of the
Exchange Act, or a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) or an entity engaged
in the business of being a broker dealer.

 

(c)Experience
of Such Investor. The Investor, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Common
Shares, and has so evaluated the merits and risks of such investment. The Investor understands that it must bear the economic risk
of this investment in the Common Shares indefinitely, and is able to bear such risk and is able to afford a complete loss of such
investment.

 

    	-10-

    	 

    

 

(d)Access
to Information. The Investor acknowledges that it has reviewed the Disclosure Materials and has been afforded: (i) the
opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning
the terms and conditions of the offering of the Common Shares and the merits and risks of investing in the Common Shares; (ii) access
to information (other than material non-public information) about the Company and its financial condition, results of operations,
business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is
necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor any other investigation
conducted by or on behalf of the Investor or its representatives or counsel shall modify, amend or affect the Investor’s
right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s representations and warranties
contained in the Transaction Documents. The Investor acknowledges receipt of copies of the SEC Reports.

 

(e)No
Conflicts. The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of
the transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Investor or
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws) applicable to the Investor, except in the case of clauses (ii) and (iii) above, for such that
are not material and do not otherwise affect the ability of the Investor to consummate the transactions contemplated hereby.

 

(f)Restricted
Securities.The Investor understands that the Common Shares are characterized as “restricted securities” under
the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act
only in certain limited circumstances.

 

ARTICLE IV

OTHER AGREEMENTS OF THE PARTIES

 

4.1Furnishing
of Information. Until the date that the Investor (and any transferee) owning Common Shares may sell all of them under Rule
144 of the Securities Act (or any successor provision), the Company covenants to use its commercially reasonable efforts to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act. The Company further covenants that it will take such further action
as any holder of Common Shares may reasonably request to satisfy the provisions of this Section 4.1.

 

    	-11-

    	 

    

 

4.2Use
of Proceeds. The Company intends to use the net proceeds from the sale of the Common Shares for working capital and general
corporate purposes. Pending these uses, the Company intends to invest the net proceeds from this offering in short-term, interest-bearing,
investment-grade securities, or as otherwise pursuant to the Company's customary investment policies

 

4.3Securities
Laws Disclosure. Promptly following the execution and delivery of this Agreement, the Company shall issue a press release (the
“Press Release”) disclosing all material terms of this Agreement and shall file with the SEC a Current Report
on Form 8-K (“8-K”) describing the material terms of this Agreement and the transactions contemplated thereby.
Notwithstanding the foregoing, the Company shall give Investor a reasonable opportunity to review and comment on such proposed
Press Release and 8-K prior to the dissemination and filing thereof, and shall consider in good faith the changes therein, if any,
requested by the Investor. The Company shall not make, or permit to be made by any of its Affiliates, any other public statement
with regard to this Agreement and the transaction contemplated hereby unless, (a) such statement is consistent with and limited
to the matters described in the Press Release and 8-K, (b) the Investor has consented in writing to such statement, or (c) such
statement, in the opinion of outside counsel to the Company, is required by law. Notwithstanding the preceding clauses (a) and
(c), the Company shall give Investor a reasonable opportunity to review and comment on such proposed public statement prior to
its dissemination, and shall consider in good faith the changes therein, if any, requested by the Investor.

 

ARTICLE V

CONDITIONS

 

5.1Conditions
Precedent to the Obligations of the Investors. The obligation of the Investor to acquire the Common Shares at the Closing is
subject to the satisfaction or waiver by the Investor, at or before the Closing, of each of the following conditions:

 

(a)Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing as though made on and as of such date;

 

(b)Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing;

 

    	-12-

    	 

    

 

(c)No
Suspensions of Trading in Common Stock. Trading in the Common Stock shall not have been suspended by the SEC or any other applicable
authority at any time since the date of execution of this Agreement; and

 

(d)Absence
of Litigation. No action, suit or proceeding by or before any court or any governmental body or authority, against the Company
or pertaining to the transactions contemplated by this Agreement or their consummation, shall have been instituted on or before
the Closing Date, which action, suit or proceeding would, if determined adversely, have a Material Adverse
Effect.

 

5.2Conditions
Precedent to the Obligations of the Company. The obligation of the Company to sell the Common Shares at the Closing is subject
to the satisfaction or waiver by the Company, at or before the Closing, of each of the following conditions:

 

(a)Representations
and Warranties. The representations and warranties of the Investor contained herein shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made on and as of such date; and

 

(b)Performance.
The Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by the Investor at or prior to the Closing.

 

ARTICLE VI

REGISTRATION RIGHTS

 

6.1Piggy-Back
Registration Rights. If at any time after the Closing Date, the Company shall determine to prepare and file with the SEC a
registration statement relating to an offering for its own account or the account of others under the Securities Act of any of
its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents
relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities
issuable in connection with stock option or other employee benefit plans, then the Company shall send to the Investor, provided
it is not then eligible to sell all of its Registrable Securities under Rule 144 in a three-month period, written notice of such
determination and if, within ten (10) days after receipt of such notice, the Investor shall so request in writing, the Company
shall include in such registration statement all or any part of such Registrable Securities the Investor requests to be registered.
The Investor agrees to furnish to the Company a completed selling stockholder questionnaire in customary form and further agrees
that it shall not be entitled to the inclusion of its Registrable Securities unless it has returned such questionnaire to the
Company. Notwithstanding the foregoing, in the event that, in connection with any underwritten
public offering, the managing underwriter(s) thereof shall impose a limitation on the number of shares of Common Stock which may
be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate
such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration
Statement only such limited portion of the Registrable Securities with respect to which the Investor has requested inclusion hereunder
as the underwriter shall permit; provided, however, that (i) the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not contractually entitled to inclusion
of such securities in such Registration Statement or are not contractually entitled to pro rata inclusion with the Registrable
Securities and (ii) after giving effect to the immediately preceding proviso, any such exclusion of Registrable Securities shall
be made pro rata among the Investor and the holders of other securities having the contractual right to inclusion of their securities
in such Registration Statement by reason of demand registration rights, in proportion to the number of Registrable Securities
or other securities, as applicable, sought to be included by the Investor or other holder. If an offering in connection with which
the Investor is entitled to registration under this Section 6.1 is an
underwritten offering, then the Investor whose Registrable Securities are included in such Registration Statement shall, unless
otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter
or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock
included in such underwritten offering and shall enter into an underwriting agreement in a form and substance reasonably satisfactory
to the Company and the underwriter or underwriters.

 

    	-13-

    	 

    

 

6.2Registration
Expenses. The Company shall pay all fees and expenses incident to the performance of or compliance with Article VI of
this Agreement by the Company, including without limitation (a) all registration and filing fees and expenses, including without
limitation those related to filings with the SEC, any Trading Market and in connection with applicable state securities or Blue
Sky laws, (b) printing expenses (including without limitation expenses of printing certificates for Registrable Securities),
(c) messenger, telephone and delivery expenses, (d) fees and disbursements of counsel for the Company, (e) fees and expenses
of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement,
(f) all listing fees to be paid by the Company to the Trading Market and (g) the reasonable legal fees of the Investor, not
to exceed $25,000 in the aggregate.

 

6.3Indemnification.

 

(a)Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless the Investor,
its officers, directors, partners, members, agents and employees, each Person who controls the Investor (within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners, members, agents
and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all
Losses, as incurred, arising out of or relating to (i) any misrepresentation or breach of any representation or warranty made by
the Company in this Agreement or any other agreement, certificate, instrument or document contemplated hereby, (ii) any breach
of any covenant, agreement or obligation of the Company contained in this Agreement or any other agreement, certificate, instrument
or document contemplated hereby or thereby, (iii) any cause of action, suit or claim brought or made against such Indemnified Party
(as defined in Section 6.3(c) below) by a third party (including for these purposes a derivative action brought on behalf
of the Company), arising out of or resulting from (x) the execution, delivery, performance or enforcement of this Agreement or
any other agreement, certificate, instrument or document contemplated hereby or thereby, or (y) the status of Indemnified Party
as holder of the Common Shares (unless, and only to the extent that, such action, suit or claim is based, including in part,
upon a breach of the Investor’s representations, warranties or covenants in this Agreement or any conduct by the Investor
that constitutes fraud, gross negligence or willful misconduct), or (iv) any untrue or alleged untrue
statement of a material fact contained in the Registration Statement, any Prospectus or any form of Company prospectus or in any
amendment or supplement thereto or in any Company preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus
or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except
to the extent, but only to the extent, that (A) such untrue statements, alleged untrue statements, omissions or alleged omissions
are based solely upon information regarding the Investor furnished in writing to the Company by the Investor for use therein, or
to the extent that such information relates to the Investor or the Investor's proposed method of distribution of Registrable Securities
and was reviewed and expressly approved by the Investor in writing expressly for use in the Registration Statement, or (B) with
respect to any prospectus, if the untrue statement or omission of material fact contained in such prospectus was corrected on a
timely basis in the prospectus, as then amended or supplemented, if such corrected prospectus was timely made available by the
Company to the Investor, and the Investor seeking indemnity hereunder was advised in writing not to use the incorrect prospectus
prior to the use giving rise to Losses. 

 

    	-14-

    	 

    

 

(b)Indemnification
by Investors. The Investor shall indemnify and hold harmless the Company and its directors, officers, agents and employees
to the fullest extent permitted by applicable law, from and against all Losses (as determined by a court of competent jurisdiction
in a final judgment not subject to appeal or review) arising solely out of any untrue statement of a material fact contained in
the Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising out
of or relating to any omission of a material fact required to be stated therein or necessary to make the statements therein (in
the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were
made) not misleading, but only to the extent that (i) such untrue statements or omissions are based solely upon information
regarding the Investor furnished to the Company by the Investor in writing expressly for use therein, or to the extent that such
information relates to the Investor or the Investor’s proposed method of distribution of Registrable Securities and was reviewed
and expressly approved in writing by the Investor expressly for use in the Registration Statement, such Prospectus or such form
of prospectus or in any amendment or supplement thereto. In no event shall the liability of the Investor hereunder be greater in
amount than the dollar amount of the net proceeds received by the Investor upon the sale of the Registrable Securities giving rise
to such indemnification obligation.

 

(c)Conduct
of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder
(an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought
(the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including
the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the
Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall
be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that
such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.

 

An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying
Party has agreed in writing to pay such fees and expenses; or (ii) the Indemnifying Party shall have failed promptly to assume
the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding;
or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and
the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to
exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified
Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of separate
counsel shall be at the expense of the Indemnifying Party). It shall be understood, however, that the Indemnifying Party shall
not, in connection with any one such Proceeding (including separate Proceedings that have been or will be consolidated before a
single judge) be liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties,
which firm shall be appointed by a majority of the Indemnified Parties. The Indemnifying Party shall not be liable for any settlement
of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect
of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from
all liability on claims that are the subject matter of such Proceeding.

 

    	-15-

    	 

    

 

All reasonable
fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party,
as incurred, within 20 Trading Days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately
determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require
such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that
such Indemnified Party is not entitled to indemnification hereunder).

 

(d)Contribution.
If a claim for indemnification under Section 6.3(a) or  (b) is unavailable to an Indemnified Party (by reason
of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute
to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and
Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue
or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or
relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a
party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 6.3(c), any
reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the
extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was
available to such party in accordance with its terms.

 

The parties
hereto agree that it would not be just and equitable if contribution pursuant to this Section 6.3(d) were determined by
pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 6.3(d), the Investor shall not
be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by
the Investor from the sale of the Registrable Securities subject to the Proceeding exceed the amount of any damages that the Investor
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation.

 

    	-16-

    	 

    

 

The indemnity and contribution
agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.

 

ARTICLE VII

MISCELLANEOUS

 

Termination.
This Agreement may be terminated by the Company or the Investor, by written notice to the other party, if the Closing has not been
consummated by 5:00 p.m. (New York City time), on the tenth Trading Day after the
date of this Agreement; provided that no such termination will affect the right of any party to sue for any breach
by the other party.

 

7.1Fees and
Expenses. Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes
and other taxes and duties levied in connection with the sale and issuance of the applicable Securities.

 

7.2Entire Agreement.
This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into
t. At or after the Closing, and without further consideration, the Company will execute and deliver to the Investors such further
documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction
Documents.

 

7.3Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile or email at the facsimile number or email address specified in this Section  prior to 6:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered
via facsimile or email at the facsimile number or email address specified in this Section on a day that is not a Trading Day or
later than 6:30 p.m. (New York City time) on any Trading Day, (c) the Trading Day following the date of deposit with a nationally
recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given.
The addresses, facsimile numbers and email addresses for such notices and communications are those set forth on the signature pages
hereof, or such other address or facsimile number as may be designated in writing hereafter, in the same manner, by any such Person.

 

    	-17-

    	 

    

 

7.4Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by the Company and the Investor or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

7.5Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

7.6Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Investor. The Investor may assign its rights under this Agreement to any Person to whom the Investor assigns or transfers any
Common Shares, provided (i) such transferor agrees in writing with the transferee or assignee to assign such rights, and
a copy of such agreement is furnished to the Company after such assignment, (ii) the Company is furnished with written notice of
(x) the name and address of such transferee or assignee and (y) the Registrable Securities with respect to which such registration
rights are being transferred or assigned, (iii) following such transfer or assignment, the further disposition of such securities
by the transferee or assignee is restricted under the Securities Act and applicable state securities laws, (iv) such transferee
agrees in writing to be bound, with respect to the transferred Common Shares, by the provisions hereof that apply to the “Investor”
and (v) such transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable
thereto.

 

7.7No Third-Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that each Indemnified
Party is an intended third party beneficiary of Section 6.3 and (in each case) may enforce the provisions of such Section
directly against the parties with obligations thereunder.

 

    	-18-

    	 

    

 

7.8Governing
Law; Venue; Waiver of Jury Trial. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

 

7.9Survival.
The representations and warranties, agreements and covenants contained herein shall survive the Closing.

 

7.10Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an original thereof.

 

7.11Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

7.12Replacement
of Securities. If any certificate or instrument evidencing any Common Shares is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss,
theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement
to indemnify and hold harmless the Company for any losses in connection therewith.

 

7.13Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Investors and the Company will be entitled to seek specific performance under the Transaction Documents. The parties agree
that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in
the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection
with any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

7.14Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference in any
Transaction Document to a number of shares or a price per share shall be amended to appropriately account for such event.

 

[SIGNATURE PAGES TO FOLLOW]

 

    	-19-

    	 

    

Execution Copy

 

Company Signature
Page

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.

 

	 	Titan Pharmaceuticals, Inc.	 
	 	 	 	 
	 	By:  	/s/ Marc Rubin	 
	 	 	Marc Rubin	 
	 	 	Executive Chairman 	 

 

	 	Address for Notice:
	 	 
	 	Facsimile
    No.:                                                
	 	Telephone No.: _______________________
	 	Attn:  ________________________
	 	 
	 	With a copy to:
	 	 
	 	Loeb & Loeb LLP
	 	345 Park Avenue, New York, NY 10154
	 	Facsimile:  (212) 214-0706
	 	Telephone: (212) 407-4935
	 	Attn:  Fran Stoller, Esq.

 

    	 

    	 

    

 

Investor Signature Page

 

By
its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms
and conditions of the Stock Purchase Agreement dated as of November 12, 2013 (the “Agreement”)
by and among Titan Pharmaceuticals, Inc. and the Investors (as defined therein), as to the number of shares of Common Stock set
forth below, and authorizes this signature page to be attached to the Purchase Agreement or counterparts thereof.

 

	 	Name of Investor:	 
	 	 	 
	 	BRAEBURN PHARMACEUTICALS SPRL	 
	 	 	 
	 	By: 	/s/ Seth L. Harrison	 
	 	 	Seth L. Harrison	 
	 	 	Authorized Signatory	 
	 	 	 	 
	 	Address:	 
	 	 	 	 
	 	 	Braeburn Pharmaceuticals Sprl	 
	 	 	c/o Apple Tree Partners	 
	 	 	47 Hulfish Street, Suite 441	 
	 	 	Princeton NJ 08542	 
	 	 	 	 
	 	Facsimile No.:  ________________	 
	 	Telephone No.: ________________	 
	 	Attn:  _________________	 
	 	 	 
	 	With a copy to:	 
	 	 	 
	 	 	Proskauer Rose LLP	 
	 	 	Eleven Times Square	 
	 	 	New York, NY  10036	 
	 	 	Facsimile:  (212) 969-2900	 
	 	 	Telephone: (212) 969-3000	 
	 	 	Attn:  Robert A. Cantone, Esq.	 
	 	 	 	 
	 	Number of Shares:  6,250,000	 
	 	Price Per Share:  $0.80	 
	 	Aggregate Purchase Price: $5,000,000	 

    

    	-2-

    	 

    

 

Exhibit A

 

OPINION OF COMPANY COUNSEL

 

1.The Company is
a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware.

 

2.The Company has
all necessary corporate power and authority to execute and deliver the Agreement, to perform its obligations thereunder and to
consummate the transactions contemplated thereby.

 

3.The Company has
all necessary power and authority to issue and deliver the Common Shares; the Common Shares have been duly authorized, and, when
duly issued and delivered to the Investor, will be duly and validly issued, fully paid and nonassessable and will be issued in
compliance with federal and state securities laws. None of the Common Shares will be issued in violation of any preemptive rights,
rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.

 

4.Assuming the
accuracy of the representations and warranties of the Investors contained in the Agreement and the compliance of such parties with
the agreements set forth herein and therein, it is not necessary, in connection with the issuance and sale of the Common Shares,
in the manner contemplated by the Agreement, to register the Securities under the Securities Act.

 

    	-3-CONFIDENTIAL
TREATMENT REQUESTED.

INFORMATION
FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN

REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE

CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS

ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.

Execution
Copy

 

Braeburn Pharmaceuticals Sprl

c/o Apple Tree Partners

47 Hulfish Street, Suite 441

Princeton NJ 08542

 

November 12, 2013

 

Titan Pharmaceuticals, Inc.

400 Oyster Point Blvd., Suite 505

South San Francisco, CA 94080-1921

Reference is made to the License Agreement
(the “Original License”) dated December 14, 2012 between Titan Pharmaceuticals, Inc. (“Titan”)
and Braeburn Pharmaceuticals Sprl (“Braeburn”), as amended by written agreement dated May 28, 2013 (the “First
Amendment”) and written agreement dated July 3, 2013 (the “Second Amendment”) (together, the Original
License, the First Amendment and the Second Amendment comprise the “Agreement”). Contemporaneously with the
execution and delivery of this letter agreement, Titan and Braeburn are entering into a Stock Purchase Agreement (the “SPA”)
with respect to the purchase by Braeburn from Titan of shares of Titan common stock.

 

This is to confirm our agreement as follows:

 

1.     
This letter agreement further amends the Agreement; provided,
however, that this letter agreement and such amendments shall not be effective unless and until the completion of the Closing under
the SPA. If the SPA is terminated prior to such Closing, this letter agreement shall automatically terminate.

 

2.     
Section 1 of the Agreement is hereby amended as follows:

 

		a.	Section 1.17 is hereby amended to read in its entirety as follows:

 

“1.17 “Commercially
Reasonable Efforts” means, with respect to (a) Braeburn, that degree of skill, effort, expertise, and resources normally
used (including the promptness in which such efforts and resources would be applied) consistent with standards generally accepted
in the pharmaceutical industry, including with respect to the diligent development, manufacture and commercialization of pharmaceutical
products of similar market and profit potential at a similar stage in development or product life as the Product; provided, however,
that in determining the level of efforts and resources to be employed, Braeburn shall not be permitted to take into account any
Second Product being developed or commercialized by Braeburn or any of its Affiliates, and (b) Titan, that degree of skill, effort,
expertise, and resources normally used (including the promptness in which such efforts and resources would be applied) consistent
with standards generally accepted in the pharmaceutical industry.”

 

    	 

    	Page 2 of 6

    

 

		b.	The following new Section 1.95 is hereby added:

 

“1.95 “Second
Product” means a product that entails the continuous delivery for more than ten (10) days of a therapeutic agent for
the treatment of the Initial Indication in the Territory.”

 

3.     
Section 2.5(a) of the Agreement is hereby amended to read in
its entirety as follows:

 

“(a)During
the Agreement Term, (i) Braeburn will not Promote, or permit its Affiliates to Promote, market or sell any product that entails
the continuous delivery for more than ten (10) days of a therapeutic agent for the treatment of the Initial Indication in the Territory,
or acquire, or permit its Affiliates to acquire, directly or indirectly any rights or interest in or to any such product that is
being Promoted, marketed or sold in the Territory, other than Product licensed to Braeburn under this Agreement, unless Braeburn
complies with the provisions of Section 6.2(c) hereof with respect to such product; and (ii) Titan will not Promote, or permit
its Affiliates to Promote, market or sell any product that entails the continuous delivery of a therapeutic agent for the treatment
of the Initial Indication in the Territory, or acquire, or permit its Affiliates to acquire, directly or indirectly any rights
or interest in or to any such product that is being Promoted, marketed or sold in the Territory.

 

4.     
Section 6.1(b) of the Agreement is hereby amended to read in
its entirety as follows:

 

“(b)
Regulatory Milestones. Braeburn shall pay to Titan, by wire transfer of immediately available
funds to an account designated by Titan, the applicable non-refundable, non-creditable, one-time milestone payment after achievement
of each milestone event as set forth below. Titan shall notify Braeburn in writing within five (5) Business Days of achievement
of the first milestone event listed in the table below and the corresponding milestone payment shall be due within ten
(10) Business Days of receipt by Braeburn of such notice. Each other milestone payment listed
in the table below shall be due within ten (10) Business Days after achievement of the corresponding milestone event.

 

	Milestone Event:	 	Milestone Payment:
	 	 	 
	(i)  FDA Approval of Product NDA	 	US$15,000,000 (fifteen million dollars)
	 	 	 
	(ii) Submission of NDA for Subsequent Indication of chronic pain	 	US$[*******]([**********] dollars)
	 	 	 
	(iii) FDA Approval of NDA for Subsequent Indication of chronic pain	 	US$[*******]([**********] dollars)
	 	 	 
	(iv) Submission of NDA for each additional Subsequent Indication (i.e., not for chronic pain)	 	US$[*******]([**********] dollars)
	 	 	 
	(v) FDA Approval of NDA for each additional Subsequent Indication (i.e., not for chronic pain)	 	US$[*******]([**********] dollars)”

 

    	 

    	Page 3 of 6

    

 

5.     
Section 6.1(c) of the Agreement is hereby amended to read in
its entirety as follows:

 

“(c)
Sales Milestones. With respect to the first achievement of each of the applicable milestone events set forth below, Braeburn
shall pay to Titan by wire transfer of immediately available funds to an account designated by Titan, the applicable non-refundable,
non-creditable, sales milestone payment listed below, within sixty (60) Business Days after the end of the Calendar Quarter in
which the applicable milestone event is first achieved:

	Milestone Event:	 	Milestone Payment:
	 	 	 
	(i)  The first time Net Sales in the Territory in a Royalty Period exceed US$[*******]([**********] dollars)	 	US$[*******]([**********] dollars)
	 	 	 
	(ii)  The first time Net Sales in the Territory in a Royalty Period exceed US$[*******]([**********] dollars)	 	US$[*******]([**********] dollars)
	 	 	 
	(iii)  The first time Net Sales in the Territory in a Royalty Period exceed US$[*******]([**********] dollars)	 	US$[*******]([**********] dollars)
	 	 	 
	(iv)  The first time Net Sales in the Territory in a Royalty Period exceed US$[*******]([**********] dollars)	 	US$[*******]([**********] dollars)
	 	 	 
	(v)  The first time Net Sales in the Territory in a Royalty Period exceed

 US[*******]([**********])	 	US$[*******]([**********] dollars)”

  

Each of the milestone payments
set forth in this Section 6.1(c) shall be payable once.  If any milestone event listed above occurs in the same
Calendar Year as any other milestone event listed above, Braeburn shall pay the milestone payments related to each such milestone
event that occurs in such Calendar Year.”

 

6.     Section 6.2 of the Agreement is hereby amended to read in its
entirety as follows:

 

“6.2   Royalties.

 

(a)              
In consideration of the rights granted by Titan hereunder, during the Agreement Term, Braeburn shall pay Titan royalties on aggregate
Net Sales in the Territory in each Calendar Year (“Royalties”) at the following
rates:

 

    	 

    	Page 4 of 6

    

 

	Aggregate Net Sales of Licensed 

Products in Territory during Calendar 

Year:	 	
        Royalty

        (% of Aggregate Net Sales of

        Licensed Products

        in the Territory during a Calendar Year)

	(i)  Less than or equal to US$[*****]([******] dollars)	 	 	[*****]%
	
         
	 	 	 
	(ii)  Greater than US[*****]([*****]dollars), but less than or equal to US$[*******]([******] dollars)	 	 	[*****]%
	 	 	 	 
	(iii)  Greater than US$[******]([******] dollars)	 	 	[*****]%

 

(b)              
Notwithstanding the above, on a country-by-country basis, upon the occurrence of any Competition, the
Royalties otherwise payable by Braeburn to Titan under Section 6.2(a) shall be reduced to [*****]
percent ([*****]%) of Net Sales, provided that for the Calendar Year in which such
Competition occurs, the reduction in Royalties shall be applicable only from and after the effective date of such Competition.

 

(c)               
If Braeburn (i) sells in the Territory, or permits any of its Affiliates to sell in the Territory, a Second Product, or (ii) acquires,
or permits its Affiliates to acquire, directly or indirectly, any rights or interest in or to a Second Product that is being sold
in the Territory, Titan shall be entitled to receive aggregate royalties of up to fifty million dollars(US$50,000,000 dollars)
at the rate of [*****]percent ([*****]%) of aggregate
net sales of the Second Product in the Territory. For the avoidance of doubt, all such royalties shall be aggregated for purposes
of the fifty million dollars(US$50,000,000 maximum amount, regardless of the number of calendar years over which such royalties
are paid. With repect to such royalties, (i) Section 6.4 (Reports and Payments), 6.5 (Taxes), and 6.6 (Audits) shall apply to the
royalties on net sales of the Second Product to the same extent such Sections apply to Net Sales of Licensed Products, and (ii)
net sales of the Second Product shall be determined in a manner consistent with the determination of Net Sales of Licensed Products.

 

(d)Following
the first written notice by Braeburn to Titan that Braeburn intends to (i) Promote, market or sell in the Territory, or permit
any of its Affiliates to Promote, market or sell in the Territory, a specific product (other than a Licensed Product or a Second
Product) that entails the continuous delivery of a therapeutic agent for the treatment of any substance addiction (an “Addiction
Product”), or (ii) acquire, or permit its Affiliates to acquire, directly or indirectly,
any rights or interest in or to an Addiction Product that is being developed, Promoted, marketed or sold in the Territory (in either
case, an “Addiction Product Notice”), Titan may, in its sole discretion, irrevocably
elect to (x) reduce the Royalty rate provided for in Section 6.2(a)(i) from [*******]
percent ([*******]%) to [*******] percent ([*******]%),
and (y) receive aggregate royalties of up to [*******]([**********]) at the rate of [*******]
percent ([*******]%) of aggregate net sales of the Addiction Product in the Territory
(the “Addiction Product Election”). For the avoidance of doubt, all such royalties
shall be aggregated for purposes of the [*******]([**********]) maximum amount, regardless
of the number of calendar years over which such royalties are paid. To make the Addiction Product Election, Titan must provide
Braeburn written notice thereof within thirty (30) days after Braeburn gives Titan the Addiction Product Notice. If the Addiction
Product Election is timely made by Titan, (A) the Addiction Product Election shall be effective on the date of the first sale to
a Third Party of a Addiction Product in a given regulatory jurisdiction in the Territory for monetary value after Regulatory Approval
has been obtained in such jurisdiction, (B) Section 6.4 (Reports and Payments), 6.5 (Taxes), and 6.6 (Audits) shall apply to the
royalties on net sales of the Addiction Product to the same extent such Sections apply to Net Sales of Licensed Products, and (C)
net sales of the Addiction Product shall be determined in a manner consistent with the determination of Net Sales of Licensed Products.”

 

    	 

    	Page 5 of 6

    

 

7.     
The first two sentences of Section 4.1(a) of the Agreement are
hereby amended to read in their entirety as follows: 

 

“Prior to May 28, 2013,
Titan will be solely responsible for all costs associated with, or required for the approval of, the Product by the FDA in the
Territory. During the period commencing on May 28, 2013 and ending on the NDA Transfer Date, Braeburn shall be solely responsible
for all costs associated with, or required for approval of, the Product by the FDA in the Territory with the exception of legal
and consulting fees and expenses incurred by Titan. For the avoidance of doubt, the fees and expenses of FoxKiser LLP pursuant
to the Professional Services Agreement dated as of June 1, 2013 shall be the sole responsibility of Braeburn. After the NDA Transfer
Date, Braeburn will be solely responsible for all costs associated with, or required for the approval of,
the Product by the FDA in the Territory.”

 

8.     
Promptly following the execution and delivery of this letter
agreement and the SPA, Titan shall issue a press release (the “Press Release”) disclosing all material terms
of this letter agreement and shall file with the SEC a Current Report on Form 8-K (“8-K”) describing the material
terms of this letter agreement and the transactions contemplated by this letter agreement. Notwithstanding the foregoing, (a) Titan
shall give Braeburn a reasonable opportunity to review and comment on such proposed Press Release and 8-K prior to the dissemination
and filing thereof, and shall consider in good faith any changes therein requested by Braeburn; (b) Titan shall seek from the Securities
and Exchange Commission (“SEC”) confidential treatment of all financial terms of this letter agreement to the
extent such financial terms have not been previously disclosed publicly; and (c) Titan shall not disclose any such financial terms
for which confidential treatment has been granted by the SEC. Titan shall not make, or permit to be made by any of its Affiliates,
any other public statement with regard to this letter agreement unless, (i) such statement is consistent with and limited to the
matters described in the Press Release and 8-K, (ii) in the opinion of outside counsel to Titan, such statement is required by
law, or (iii) Braeburn has consented in writing to such statement. Notwithstanding the preceding clauses (i) and (ii), Titan shall
give Braeburn a reasonable opportunity to review and comment on such proposed public statement prior to its dissemination, and
shall consider in good faith any changes therein requested by the Braeburn.

 

9.     
In all other respects, the License Agreement shall remain in
full force and effect and shall be unaffected by this letter agreement.

 

[Signature page follows]

 

    	 

    	Page 6 of 6

    

 

[Signature page to letter agreement dated
November 12, 2013]

 

	 	BRAEBURN PHARAMACEUTICALS SPRL	 
	 	 	 
	 	By:	/s/Seth L. Harrison 	 
	 	 	Seth L. Harrison	 
	 	 	Authorized Signatory	 
	 	 	 	 
	 	Agreed:	 
	 	 	 
	 	TITAN PHARMACEUTICALS, INC.	 
	 	 	 
	 	By:	/s/Marc Rubin	 
	 	 	Marc Rubin	 
	 	 	Executive Chairman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]